Bioextrax AB (BIOEX) AI Stock Analysis

• Market Cap: €126.74M
• Dividend Yield: N/A
• Average Volume (3M): 68.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: -30.52%
• EPS Growth: 40.74%
• Country: SE
• Employees: 14
• Sector: Industrials
• Sector Strength: 72
• Industry: Waste Management
• EPS (TTM): -0.11
• Shares Outstanding: 39,729,134
• 10 Day Avg. Volume: 47,811
• 30 Day Avg. Volume: 68,835
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Bioextrax AB struggles with persistent financial losses, negative cash flows, and operational inefficiencies, reflected in a low financial performance score. The technical analysis indicates a lack of momentum, with the stock trading below major moving averages. Valuation metrics, particularly the negative P/E ratio, highlight concerns over financial stability and market perception. These factors collectively result in a low overall stock score.

Bioextrax AB Business Overview & Revenue Model

Company Description

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.

How the Company Makes Money

Bioextrax AB makes money primarily through licensing its proprietary technologies to companies in various industries seeking sustainable solutions for waste conversion and bioplastic production. The company's revenue streams include licensing fees, royalties from industrial partners utilizing their technology, and collaborative development agreements. Strategic partnerships with companies in sectors such as packaging, agriculture, and waste management also contribute significantly to its earnings by driving the adoption of Bioextrax's environmentally friendly processes.

Bioextrax AB Financial Statement Overview

Summary

Bioextrax AB faces significant financial challenges with persistent losses and negative cash flows, undermining profitability and growth prospects. Despite a debt-free balance sheet, the company struggles with operational efficiency and cash generation, which may hinder future growth unless addressed.

Income Statement

Bioextrax AB shows a consistently negative gross profit margin, indicating that the cost of goods sold exceeds revenue. The net profit margin is also consistently negative, reflecting significant net losses. Revenue growth is unstable, with recent declines, and both EBIT and EBITDA margins are negative due to high operating expenses relative to revenue.

Balance Sheet

The company maintains a debt-free balance sheet, which is a positive indicator of financial stability. However, the return on equity is negative due to net losses, which affects shareholder value. The equity ratio is strong, suggesting a solid capital structure with equity financing outweighing liabilities.

Cash Flow

Operating cash flows are consistently negative, indicating challenges in generating cash from core operations. Free cash flow is also negative, reflecting the ongoing need for external financing. The ratios of operating and free cash flow to net income reflect the company's difficulty in translating accounting profits into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	793.00K	515.00K	2.06M	395.00K	275.76K	21.78K
Gross Profit	-348.00K	-915.00K	718.00K	-18.64M	-11.29M	-5.75M
EBITDA	-11.20M	-16.18M	-20.65M	-18.19M	-10.18M	-5.40M
Net Income	-12.05M	-17.34M	-21.51M	-18.67M	-10.53M	-5.57M
Balance Sheet
Total Assets	20.06M	29.00M	22.52M	37.92M	12.64M	3.03M
Cash, Cash Equivalents and Short-Term Investments	10.79M	17.27M	13.40M	27.53M	8.98M	2.05M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	2.09M	2.94M	1.98M	6.15M	5.14M	1.38M
Stockholders Equity	17.97M	26.06M	20.54M	31.77M	7.50M	1.65M
Cash Flow
Free Cash Flow	-10.39M	-18.99M	-24.41M	-24.38M	-9.45M	-4.32M
Operating Cash Flow	-10.18M	-18.78M	-23.31M	-17.60M	-8.48M	-4.17M
Investing Cash Flow	-215.00K	-215.00K	-1.10M	-6.78M	-975.13K	-151.00K
Financing Cash Flow	14.22M	22.86M	10.28M	42.94M	16.38M	5.79M

Bioextrax AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.29, below the 50-day MA of 3.44, and below the 200-day MA of 3.04, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.60 is Neutral, neither overbought nor oversold. The STOCH value of 13.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SES	56 Neutral	1.57B	-22.95	-9.52%	―	-33.10%	-376.11%
SAXG	52 Neutral	79.91M	-13.27	-26.01%	―	-16.65%	97.57%
AXOLOT	43 Neutral	132.73M	-7.84	0.00%	―	-34.39%	48.09%
CIRCHE	41 Neutral	76.39M	35.12	-2.34%	―	0.00%	0.00%
BOMILL	36 Underperform	64.12M	-3.70	0.00%	―	-34.86%	9.89%
BIOEX	32 Underperform	€126.74M	―	-87.33%	―	-30.52%	40.74%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%